Skip to main content
Porton Pharma Solutions Ltd. logo

Porton Pharma Solutions Ltd. — Investor Relations & Filings

Ticker · 300363 ISIN · CNE100001S57 LEI · 300300IQTJFHA0YRXE68 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,163 across all filing types
Latest filing 2025-10-24 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300363

About Porton Pharma Solutions Ltd.

https://www.porton.cn

Porton Pharma Solutions Ltd. is a global contract development and manufacturing organization (CDMO) providing end-to-end solutions for the pharmaceutical and biotechnology sectors. The company specializes in the development and manufacturing of small molecule APIs, intermediates, and drug products, while expanding its capabilities into biologics and cell and gene therapies. Its service portfolio encompasses process research and development, analytical services, pilot-scale production, and large-scale commercial manufacturing. Porton operates a network of R&D centers and manufacturing facilities designed to meet international regulatory standards, including those of the FDA and EMA. By leveraging an integrated technology platform, the company supports clients throughout the entire drug lifecycle, from preclinical development to commercialization, focusing on operational excellence and supply chain security.

Recent filings

Filing Released Lang Actions
第六届董事会第四次临时会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of resolutions passed at the sixth board of directors' fourth extraordinary meeting of Chongqing Boteng Pharmaceutical Technology Co., Ltd. It includes voting results on various proposals such as approval of the 2025 Q3 report, asset impairment provisions, and revisions to company policies. The document references other filings where the full reports or detailed content are published (e.g., the 2025 Q3 report and asset impairment announcement). The document is short (1547 characters) and primarily serves as a formal announcement of board decisions rather than containing full financial statements or detailed management discussion. It focuses on board meeting resolutions and governance matters, including policy revisions and audit committee approvals. Therefore, it fits best under Board/Management Information (MANG) as it announces board meeting resolutions and management decisions rather than being a full report or financial statement.
2025-10-24 Chinese
内部审计管理制度（2025年10月）
Governance Information Classification · 95% confidence The document is titled '内部审计管理制度' (Internal Audit Management System) and is a detailed internal control and audit policy document for 重庆博腾制药科技股份有限公司. It outlines the internal audit framework, responsibilities, procedures, and reporting requirements. It references regulatory frameworks and internal governance but does not contain financial statements, earnings data, or shareholder meeting materials. It is a governance-related document focused on internal audit and control policies rather than a financial report or announcement. Therefore, it fits best under Governance Information (CGR). The document length (6610 characters) and content confirm it is a full policy document, not a brief announcement or certification.
2025-10-24 Chinese
董事会秘书工作制度（2025年10月）
Governance Information Classification · 95% confidence The document is titled '董事会秘书工作制度' which translates to 'Board Secretary Work System'. It outlines the duties, qualifications, appointment, and responsibilities of the company's board secretary. It references relevant laws, stock exchange rules, and company bylaws. The content is focused on governance practices and internal rules related to the board secretary role rather than financial results, audit opinions, or shareholder meeting materials. The document is about governance structure and internal company policies, not a report or announcement of financial or operational results. Therefore, it fits best under Governance Information (CGR). The document length is 3104 characters, which is consistent with a detailed governance policy document rather than a brief announcement or report publication notice.
2025-10-24 Chinese
关于2025年前三季度计提资产减值准备及部分资产报废的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by Chongqing Boteng Pharmaceutical Technology Co., Ltd. regarding the provision for asset impairment and disposal of certain assets for the first three quarters of 2025. It details the amounts of impairment provisions for accounts receivable, inventory, contract assets, and fixed assets scrapped. The document states that these provisions will be reflected in the 2025 third quarter financial report but does not itself contain comprehensive financial statements or detailed financial analysis. The document is relatively short (1317 characters) and serves as a disclosure of a specific accounting event rather than a full interim or annual financial report. It is not a certification or a regulatory compliance filing. Therefore, it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous announcements that do not fit other specific categories.
2025-10-24 Chinese
2025年三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "第三季度报告" which translates to "Quarterly Report" and is explicitly labeled as the 2025 third quarter report for 重庆博腾制药科技股份有限公司. It contains detailed financial data including income statement, balance sheet, cash flow statement, and extensive financial metrics for the quarter and year-to-date periods. The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement. The content includes comprehensive financial statements and management commentary on financial performance, consistent with an Interim / Quarterly Report. There is no indication that this is an Annual Report, Earnings Release, or any other filing type. Therefore, the correct classification is Interim / Quarterly Report (IR).
2025-10-24 Chinese
2025年前三季度业绩预告
Earnings Release Classification · 95% confidence The document is a performance forecast for the first three quarters of 2025, providing estimated net profit and revenue figures. It explicitly states that the financial data is preliminary, unaudited, and will be detailed in the upcoming third quarter report. The document is short (885 characters) and serves as an announcement of expected financial results rather than a full interim or quarterly report containing actual financial statements. Therefore, it fits the category of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only.
2025-10-13 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.